Eli Lilly reported top-line results from the Attain-1 phase 3 trial of orforglipron, its oral GLP-1 receptor agonist for obesity treatment. The highest dose resulted in an average weight loss of 11.2% after 72 weeks, which was below the 15-21% typically seen with injectable GLP-1 therapies like Novo Nordisk's Wegovy or Lilly's Zepbound. Despite meeting primary endpoints, the data temper expectations for orforglipron's competitiveness in a landscape dominated by high-efficacy injectables. Lilly plans to submit regulatory filings by year-end and is exploring maintenance therapy applications. The outcome underscores the challenges facing oral obesity therapies in replicating the success of injectables.